DBC1, a novel native inhibitor of anti-aging protein SIRT1

Details DBC1, a novel native inhibitor of anti-aging protein SIRT1 DBC1, a novel native inhibitor of anti-aging protein SIRT1

2008-05-23

2011-10-25

Vivlemore, Tracy (Department: 1635)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

Reexamination Certificate

active

08043804

ABSTRACT:
A novel complex is identified between the NAD-dependent deacetylase, SIRT1 and its novel inhibitor, DBC1. Provided herein are methods to identify a compound that inhibits the complexation between SIRT1 and DBC1. Exemplary methods comprise contacting either the complexation between DBC1 and SIRT1 with an agent being tested for its ability to inhibit the complexation between SIRT1 and DBC1. Also, provided are methods to identify a compound that increases the complexation between SIRT1 and DBC1. Exemplary methods comprise contacting either the complexation between DBC1 and SIRT1 with an agent being tested for its ability to increase the complexation between SIRT1 and DBC1. Further, methods are provided to increase or decrease SIRT1 activity by contacting the complexation between SIRT1 and DBC1 with a peptide that either decreases or increases the complexation between SIRT1 and DBC1. Further, methods are provided for the treatment of patients suffering from diseases including metabolic diseases including obesity and diabetes, and neurodegenerative disorders including Alzheimer's disease and Huntington's disease using compounds that inhibit the complexation between SIRT1 and DBC1.

REFERENCES:
patent: 4690918 (1987-09-01), Beppu et al.
patent: 7241743 (2007-07-01), Gu et al.
patent: 2002/0183388 (2002-12-01), Gudas et al.
patent: 2003/0207325 (2003-11-01), Guarente et al.
patent: 2004/0029134 (2004-02-01), Gu et al.
patent: 2005/0037345 (2005-02-01), Inazawa et al.
patent: 2008/0119434 (2008-05-01), Gu et al.
patent: WO/02/102981 (2002-12-01), None
patent: WO/2004/053142 (2004-06-01), None
Oct. 6, 2004 Office Action issued from the United States Patent and Trademark Office in connection with U.S. Appl. No. 10/172,706.
Apr. 29, 2005 Final Office Action issued from the United States Patent and Trademark Office in connection with U.S. Appl. No. 10/172,706.
Dec. 29, 2005 Final Office Action issued from the United States Patent and Trademark Office in connection with U.S. Appl. No. 10/172,706.
Sep. 6, 2006 Office Action issued from the United States Patent and Trademark Office in connection with U.S. Appl. No. 10/172,706.
Mar. 5, 2007 Notice of Allowability issued from the United States Patent and Trademark Office in connection with U.S. Appl. No. 10/172,706.
Aug. 17, 2006 Office Action issued from the United States Patent and Trademark Office in connection with U.S. Appl. No. 10/313,203.
Jan. 24, 2007 Final Office Action issued from the United States Patent and Trademark Office in connection with U.S. Appl. No. 10/313,203.
Nov. 15, 2005 Office Action issued from the United States Patent and Trademark Office in connection with U.S. Appl. No. 10/313,203.
Sep. 30, 2009 Office Action issued from the United States Patent and Trademark Office in connection with U.S. Appl. No. 11/825,944.
PCT International Search Report issued Dec. 8, 2008 in connection with PCT International Application No. PCT/US2003/38658, filed on Dec. 4, 2003.
PCT International Search Report issued Jul. 23, 2003 in connection with PCT International Application No. PCT/US2003/38658, filed on Dec. 4, 2003.
PCT International Preliminary Examination Report issued Feb. 22, 2004 in connection with PCT International Application No. PCT/US2002/29019, filed on Jun. 14, 2002.
Jan. 6, 2005 Amendment in Response to Oct. 6, 2004 Office Action issued in connection with U.S. Appl. No. 10/172,706.
Jul. 29,2005 Amendment in Response to Apr. 29, 2005 Final Office Action issued in connection with U.S. Appl. No. 10/172,706.
Jun. 29, 2006 Communication in Response to Dec. 29, 2005 Final Office Action issued in connection with U.S. Appl. No. 10/172,706.
Dec. 6, 2006 Amendment in Response to Sep. 6, 2006 Office Action issued in connection with U.S. Appl. No. 10/172,706.
Nov. 17, 2006 Amendment in Response to Aug. 17, 2006 Office Action issued in connection with U.S. Appl. No. 10/313,203.
Gu, W. et al., (1999) “A Novel Human SRB/MED-Containing Cofactor Complex SMCC, Involved in Transcription Regulation.” Molecular Cell, vol. 3, Issue 1, pp. 97-108.
Gu, W. et al., (1997) “Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain.” Cell 90(4):595-606.
Gu, W. et al., (1997) “Synergistic Activation of Transcription by CBP and p53.” Nature 387, 819-823.
Guarente, L., (2000) “Sir2 links Chromatin Silencing, Metabolism, and Aging.” Genes Dev. 14, 1021-1026.
Landry, J., et al., (2000) “The Silencing Protein SIR2 and its Homologs are NAD-Dependent Protein Deacetylases.” Proc. Natl. Acad. Sci. U.S.A. 97, 5807-5811.
Langley, E., et al., (2002) “Human SIR2 Deacetylates p53 and Antagonizes PML/p53-Induced Cellular Senescence.” The EMBO Journal. vol. 21, No. 10, 2383-2396.
Lin, S.J., et al., (2000) “Requirement of NAD and SIR2 for Life-Span Extension by Calorie Restriction inSaccharomyces cerevisiae.” Science 289, 2126-2128.
Luo, J. et al., (Oct. 19, 2001) “Negative Control of p53 by Sir2alpha Promotes Cell Survival Under Stress.” Cell. vol. 107, No. 2, pp. 137-148.
Vaziri, H., et al., (2000) “hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase.” Cell. (107)149-159.
Baur, JA, et al. (2006) “Resveratrol improves health and survival of mice on high-calorie diet.” Nature, 444:337-342.
Baur, JA & Sinclair, D.A. (2006) “Therapeutic potential of Resveratrol: the in vivo evidence.” Nat Rev Drug Discv, 5:493-506.
Bordone, L & Guarente, L (2005) “Calorie restriction, SIRT1 and metabolism: understanding longevity.” Nat Rev Mol Cell Biol,.6:298-305.
Brunet, A, et al. (2004) “Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase.” Science, 303:2011-5.
Chen, D, et al., (2005) “Increase in activity during calorie restriction requires SIRT1.” Science, 310:1641.
Chen, WY, et al. (2005) “Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses.” Cell, 123:437-48.
Cheng, HL, et al. (2003) “Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice.” Proc Natl Acad Sci USA, 100:10794-9.
Cohen, HY, et al. (2004) “Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis.” Mol Cell, 13:627-38.
Greene, WC & Chen, LF (2004) “Regulation of NF-kappaB action by reversible acetylation.” Novartis Found Symp, 259:208-222.
Kaeberlein, M, et al., (1999) “The SIR2/3/4 Complex and SIR2 Alone Promote Longevity inSaccharomyces cerevisiaeby Two Different Mechanisms.” Genes Dev, 13:2570-2580.
Kitamura, YI, et al. (2005) “FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction.” Cell Metab, 2:153-63.
Luo, J, et al. (2000) “Deacetylation of p53 modulates its effect on cell growth and apoptosis.” Nature, 408:377-381.
Motta, MC, et al. (2004) “Mammalian SIRT1 represses forkhead transcription factors.” Cell, 116:551-63.
Nikolaev ,et al., (Jan. 10, 2003) “Parc: Cytoplasmic Anchor for p53,” Cell, 112: 29-40.
North, BJ & Verdin, E (2004) “SIRTuins: Sir2-related NAD-dependent protein deacetylases.” Genome Biol, 5:224.
Picard, F, et al. (2004) “SIRT1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma.” Nature, 429:771-776.
PRI Database, National Center for Biotechnology Information, National Library of Medicine, NIH (Bethesda, MD, U.S.A.) Accession No. AJ318215. Jun. 2002.
Rodgers, JT, et al. (2005) “Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1.” Nature, 434:113-8.
Rogina, B & Helfand, SL (2004) “Sir2 mediates longevity in the fly through a pathway related to calorie restriction.” Proc Natl Acad Sci USA, 101:15998-16003.
Tang, BL & Chua CE (Feb. 2007) “SIRT1 and neuronal diseases.” Mol Aspects Med, 29:187-200.
Tissenbaum, HA, et al., (2001) “

Affiliated with

Also associated with

Rating

DBC1, a novel native inhibitor of anti-aging protein SIRT1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with DBC1, a novel native inhibitor of anti-aging protein SIRT1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DBC1, a novel native inhibitor of anti-aging protein SIRT1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4255445